Ferroptosis is a relatively recent addition to the catalogue of programmed cell death pathways, and it behaves very differently from apoptosis. Instead of the tidy membrane blebbing and caspase activation that characterize classical apoptosis, ferroptosis is driven by an accumulation of lipid-based reactive oxygen species that overwhelm cellular antioxidant defenses, causing membrane rupture. Three ingredients are essential: iron, which catalyzes the Fenton reactions that generate destructive hydroxyl radicals; polyunsaturated fatty acids incorporated into membrane phospholipids, which serve as the fuel; and failure of the glutathione-dependent repair systems that normally keep lipid peroxidation in check. The enzyme acyl-CoA synthetase long-chain family member 4, known as ACSL4, sits near the top of this cascade, because it esterifies free polyunsaturated fatty acids so they can be inserted into membranes, effectively loading the ferroptotic gun.

Because melanocytes are professional pigment factories, they are intrinsically vulnerable to this kind of death. Melanin synthesis generates hydrogen peroxide and other reactive oxygen species as byproducts, meaning these cells live permanently on the edge of oxidative stress. Earlier work, including studies of altered ferroptosis marker expression and iron metabolism in vitiliginous skin, had suggested that the pathway might contribute to melanocyte loss, but direct measurements of circulating ferroptosis-related biomarkers in patients, correlated with clinical disease severity and activity, remained scarce. The new study set out to fill that gap.

The research team, led by dermatologists at Al-Azhar University in Cairo, enrolled 30 patients with vitiligo vulgaris and 30 age- and sex-matched healthy controls. For each participant, the investigators measured serum levels of four biomarkers: ACSL4, the lipid-peroxidation end product malondialdehyde (MDA), total reactive oxygen species (ROS), and serum iron. ACSL4, MDA and ROS were quantified with enzyme-linked immunosorbent assays, while iron was determined by a colorimetric method. On the clinical side, each patient was scored with the Vitiligo Area Scoring Index (VASI), which estimates the percentage of body surface area depigmented, and the Vitiligo Disease Activity score (VIDA), a patient-reported measure of recent flare behavior, alongside documentation of the last episode of disease activity.

The results were internally consistent and directionally coherent. Serum concentrations of ACSL4, MDA and ROS were all significantly elevated in vitiligo patients compared with controls, and the elevation was even more pronounced in patients whose disease was clinically active. Serum iron moved in the opposite direction: it was significantly lower in patients than in controls, and lowest of all in the active-disease group. In other words, the biochemical signature of ferroptosis, abundant lipid-peroxidation machinery and lipid-damage products paired with depleted circulating iron, tracked the clinical state of the disease.

The correlation analysis sharpened the picture further. ACSL4, MDA and ROS each showed significant positive correlations with VASI, VIDA and the time since the last disease activity, meaning that the more extensive and the more recently active a patient’s vitiligo was, the higher these ferroptosis markers climbed. Serum iron, by contrast, correlated negatively with both VASI and VIDA, falling as disease extent and activity rose. Notably, the biomarkers did not differ significantly across other clinical parameters examined, suggesting that their relationship is specifically with disease activity and severity rather than with demographic or anatomic features.

Interpreting these findings requires care, because serum measurements are an indirect window onto what happens inside the skin. The authors frame the pattern as evidence that ferroptosis participates in vitiligo pathogenesis, and the data are compatible with a model in which iron is mobilized from the circulation into inflamed, oxidatively stressed tissue, where it fuels lipid peroxidation in melanocyte membranes. ACSL4 upregulation would then sensitize melanocytes further by enriching their membranes with peroxidation-prone fatty acids, while MDA and ROS accumulate as the downstream wreckage of that process. The inverse relationship with serum iron fits the idea that iron is being consumed or sequestered where the damage is happening, a pattern seen in other iron-dependent pathological states.

The study also lands in the middle of a decades-long debate about oxidative stress in vitiligo. Reduced antioxidant capacity, elevated lipid peroxidation products and altered activities of enzymes such as superoxide dismutase and catalase have been reported in vitiligo patients since the 1990s, and meta-analyses have confirmed that MDA is consistently higher in patients than in controls. What the new work adds is the ferroptosis framing: rather than oxidative stress being a diffuse, nonspecific background phenomenon, the coordinated elevation of ACSL4, MDA and ROS alongside iron depletion points to a specific, druggable cell-death program as the mechanism linking oxidative damage to melanocyte disappearance.

There are, of course, limitations inherent to the design. With 30 patients and 30 controls, the study is small, and its cross-sectional nature captures a single time point, so it cannot prove that ferroptosis drives depigmentation rather than merely accompanying it. Serum biomarkers also reflect whole-body physiology and cannot distinguish melanocyte-intrinsic ferroptosis from lipid peroxidation arising in other tissues or in infiltrating immune cells. Longitudinal follow-up, tissue-level measurements in depigmented and adjacent normally pigmented skin, and comparisons before and after treatment that halts disease activity would all be needed to establish causality and to confirm that these markers fall when the disease is brought under control.

Even with those caveats, the clinical implications are tantalizing. If ACSL4, MDA, ROS and serum iron can be validated in larger cohorts as a biomarker panel, dermatologists might one day use a simple blood test to distinguish active from stable vitiligo, to predict impending flares, and to monitor response to therapy, decisions that currently rest on clinical scores and patient recall. More ambitiously, the ferroptosis pathway offers a set of concrete therapeutic targets: iron chelation, inhibitors of ACSL4 or of lipid peroxidation, and reinforcement of cellular antioxidant defenses have all shown promise in preclinical models of ferroptosis-driven injury. For a condition that affects roughly one percent of the world’s population and carries a heavy psychological burden, the prospect of intercepting the cell-death program that kills melanocytes, rather than only suppressing the immune attack around them, represents a genuinely new frontier in vitiligo research.

Subject of Research: Ferroptosis-related serum biomarkers in vitiligo vulgaris disease activity and severity

Article Title: Evaluation of ferroptosis-related biomarkers in vitiligo vulgaris

Article References: Ali, B. A.-H. A., Kamel, A. M., Elmadbouly, A. A. E., & Risha, B. E.-S. M. (2026). Evaluation of ferroptosis-related biomarkers in vitiligo vulgaris. Archives of Dermatological Research, 318(1), Article 415. https://doi.org/10.1007/s00403-026-04908-w

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04908-w

Keywords: vitiligo, ferroptosis, ACSL4, malondialdehyde, reactive oxygen species, serum iron, oxidative stress, melanocytes, VASI, VIDA, lipid peroxidation, case-control study

Ulcerative colitis is a chronic inflammatory bowel disease characterized by relentless damage to the colonic epithelium, the single-cell-thick barrier that separates the body from the trillions of microbes in the gut lumen. When this barrier fails, bacterial products flood the underlying tissue, immune cells respond, and a vicious cycle of inflammation and tissue erosion follows. For years, researchers have known that ulcerative colitis involves profound metabolic reprogramming, but the question of how those altered metabolic fluxes actually translate into epithelial injury has remained frustratingly incomplete. The new work, led by Daowei Yang, Tiantian Wang, and Jianwei Zhu with senior authors Rong Wang, Xiaolei Zhu, Sheng Zhou, and Jianhua Zou, set out to close that gap by interrogating the axis connecting metabolism, epigenetics, and ferroptosis directly in human tissue, mouse models, and cultured intestinal epithelial cells.

The team began with transcriptomic profiling of biopsy samples from ulcerative colitis patients, comparing them against healthy donor tissue, and then extended the analysis to mice given dextran sulfate sodium, a chemical that induces colitis and is a standard model of the human disease. Across both systems, a consistent picture emerged: the inflamed epithelium had undergone a glycolytic shift, the metabolic pivot in which cells ramp up glucose fermentation even in the presence of oxygen. A hallmark of this shift was elevated expression of hexokinase-2, or HK2, the enzyme that commits glucose to the glycolytic pathway, accompanied by a striking accumulation of lactate, the end product of fermentation. Lactate, once dismissed as a mere metabolic byproduct, has in recent years been recast as a signaling molecule, and this study adds a dramatic new chapter to that story.

The central molecular player in the new findings is ACSS2, short for acyl-CoA synthetase short-chain family member 2. This enzyme is best known for its role in converting acetate into acetyl-CoA, but the researchers demonstrated that in the lactate-rich environment of the inflamed colon, ACSS2 also converts lactate into lactyl-CoA. That metabolite is the essential substrate for histone lactylation, a chemical modification of histone proteins, the spools around which DNA is wound. Using CUT&Tag, a technique that maps where specific histone modifications sit across the genome, along with immunodetection methods, the team showed that lactate-derived lactyl-CoA drives lactylation of histone H3 at lysine 18, a mark abbreviated H3K18la, on the promoters of specific genes in the epithelial cells.

Here is where the feedback loop closes with almost engineered precision. The genes upregulated by the H3K18 lactylation mark include HK2, the very enzyme that fuels glycolysis and lactate production; ACSS2 itself, the enzyme that converts lactate into the epigenetic substrate; and ACSL4, acyl-CoA synthetase long-chain family member 4, an enzyme long recognized as a decisive driver of ferroptosis because it channels polyunsaturated fatty acids into membrane phospholipids, the raw material that iron-catalyzed peroxidation attacks. In other words, lactate produced by glycolysis activates an epigenetic program that commands the cell to make more glycolytic machinery, more lactate-processing enzyme, and more ferroptosis-sensitizing lipid chemistry. Each turn of the loop amplifies the next, progressively raising the epithelium’s susceptibility to lipid peroxidation and ferroptotic death.

The pathological consequences of this loop were visible throughout the disease models. Increased ferroptotic markers coincided with disruption of tight junctions, the protein seals between adjacent epithelial cells that give the gut barrier its integrity. As epithelial cells succumbed to ferroptosis, the barrier opened, inflammation deepened, and the tissue damage characteristic of ulcerative colitis advanced. The researchers also found support for a ferroptosis transcriptional program in public gene-expression datasets from ulcerative colitis patients, reinforcing the clinical relevance of the mouse and cell findings. The convergence of metabolic shift, epigenetic rewriting, and cell death execution in the same tissue samples makes a compelling case that these processes are not parallel phenomena but causally linked stages of a single disease mechanism.

To test causality directly, the team generated mice lacking Acss2 specifically in the intestinal epithelium, rather than throughout the body. When these animals were subjected to the dextran sulfate sodium colitis model, the results were striking: histone H3K18 lactylation was dampened, ACSL4 expression fell, epithelial cell viability was preserved, and colonic injury was attenuated. Importantly, the epithelium-specific deletion did not cause spontaneous abnormalities in the colon, suggesting that ACSS2 becomes pathologically relevant chiefly under inflammatory, lactate-rich conditions rather than serving an indispensable housekeeping role in healthy gut tissue. The team also traced the loop to its upstream source, identifying c-Myc, a master transcription factor and notorious oncogene, as a common activator of the program, and showed that pharmacological inhibition of c-Myc similarly suppressed the ACSS2/H3K18la/ACSL4 axis and protected the epithelium.

Perhaps the most translationally exciting element of the study is the delivery technology. Systemic administration of small interfering RNA against ACSS2 faces an obvious obstacle: getting RNA drugs into the right cells without collateral effects. The researchers engineered a butyrate-modified lipid nanoparticle, or BLNP, a delivery vehicle decorated with butyrate, a short-chain fatty acid that is naturally consumed by intestinal epithelial cells and is known to be beneficial for colonic health. When administered systemically in the colitis mice, these nanoparticles delivered ACSS2 siRNA to the epithelium, effectively knocked down the enzyme, reversed colitis pathology, restored tight junction integrity, and reduced ferroptotic injury, all without overt toxicity as judged by standard biosafety measures including liver and kidney function markers. Using the gut’s own preferred fuel as a homing beacon for a therapeutic nanoparticle is an elegant design choice that could influence how RNA drugs are targeted to the intestine more broadly.

The implications reach well beyond a single enzyme in a single disease. Histone lactylation has been implicated in macrophage polarization, tumor biology, and fibrosis, but this study is among the clearest demonstrations that the mark can function as a metabolic feedback amplifier that actively worsens tissue injury rather than merely reporting on metabolic state. By linking a disease-associated metabolic shift to a specific epigenetic mark and then to a specific mode of cell death, the work provides a template for dissecting how metabolic intermediates sculpt chromatin in other inflammatory conditions. It also elevates ACSS2 from a metabolic housekeeping enzyme to a mechanistically central and druggable node in inflammatory bowel disease. The authors conclude that targeting the lactate-fueled ACSS2/H3K18la axis represents a promising strategy to restore mucosal homeostasis, and with a working nanoparticle delivery system already validated in vivo, the path from this feedback loop to a clinical candidate may be shorter than usual. For the millions of people living with ulcerative colitis, a disease in which current therapies suppress immunity without always halting barrier destruction, the idea that a metabolic waste product can be disarmed before it rewrites the genome of gut cells is a genuinely new and hopeful direction.

Subject of Research: The role of ACSS2-dependent histone lactylation in a metabolic feedback loop driving ferroptotic epithelial injury in ulcerative colitis

Article Title: ACSS2-dependent histone lactylation amplifies ferroptotic injury via a metabolic feedback loop in ulcerative colitis

Article References: Yang, D., Wang, T., Zhu, J., Lu, Y., Shen, R., Chen, Y., Zou, J., Zhou, S., Zhu, X., & Wang, R. (2026). ACSS2-dependent histone lactylation amplifies ferroptotic injury via a metabolic feedback loop in ulcerative colitis. Genome Medicine. https://doi.org/10.1186/s13073-026-01786-9

Image Credits: AI Generated

DOI: 10.1186/s13073-026-01786-9

Keywords: ulcerative colitis, histone lactylation, ferroptosis, ACSS2, H3K18la, lactate, metabolic feedback loop, intestinal epithelial cells, lipid nanoparticles, inflammatory bowel disease, HK2, ACSL4

The study, led by Feng Li and Wenfeng Zhang along with colleagues in China, rests on a deceptively simple biological premise: cancer is not just a disease of uncontrolled growth, but of rewired metabolism. Tumor cells undergo metabolic reprogramming, altering how they consume glucose, synthesize lipids, and process amino acids to fuel their expansion. The genes that govern these processes, collectively termed metabolism-related genes, sit upstream of many of the changes clinicians currently measure. The authors argue that shifts in these regulatory genes precede changes in established tumor markers such as carbohydrate antigen 19-9, carcinoembryonic antigen, and lactic acid, making them potentially more sensitive and reliable indicators of disease course.

To test this idea, the team mined the Kyoto Encyclopedia of Genes and Genomes database for a comprehensive catalog of 3,216 metabolism-related genes. They then compared the expression of these genes between normal liver tissue and intrahepatic cholangiocarcinoma specimens using the TCGA-CHOL collection, which provided mRNA profiles and clinical data for 32 tumor samples and 8 normal controls. Rigorous statistical filtering, employing the limma framework with a false discovery rate threshold below 0.01 and absolute log2 fold changes exceeding 2, revealed a striking landscape of metabolic disruption: 1,002 differentially expressed metabolic genes, of which 717 were elevated and 285 were suppressed in tumors. Hierarchical clustering showed that these expression patterns alone were sufficient to cleanly separate cancerous from healthy tissue.

Functional enrichment analysis added biological texture to the numbers. Gene Ontology and KEGG pathway analyses indicated that the dysregulated genes clustered around the metabolism and synthesis of energy-bearing substances, catalytic activity, the chemical carcinogenesis pathway, and signaling through peroxisome proliferator-activated receptors, or PPARs. That last finding is particularly intriguing given prior evidence that PPARγ can suppress cholangiocarcinoma growth through p53-dependent pathways and that a microRNA targeting PPARγ contributes to gemcitabine resistance. The enrichment results suggest that metabolic gene dysregulation in this cancer is not random noise but converges on pathways with known roles in tumor initiation and treatment failure.

The next challenge was to compress more than a thousand candidate genes into a clinically usable predictor. The researchers first applied univariate Cox regression with a stringent significance threshold of p less than 0.005, which flagged six genes associated with elevated mortality risk: SLC16A3, B4GALNT1, ACSL4, MTHFD1L, PYGB, and AGPAT4. They then turned to LASSO Cox regression, a machine-learning technique that shrinks the coefficients of less informative variables toward zero to guard against overfitting in small datasets. With three-fold cross-validation and an optimal penalty parameter of 0.1196, the model settled on four genes. The resulting risk score is a weighted sum of their expression levels, with MTHFD1L carrying the largest coefficient at 0.059857, followed by ACSL4, PYGB, and SLC16A3.

The performance of this compact signature was remarkable. When patients in the TCGA cohort were split into high-risk and low-risk groups at the median score, Kaplan-Meier analysis showed dramatically worse overall survival in the high-risk category. More striking still, receiver operating characteristic analysis yielded an area under the curve of 0.994 for the risk score, dwarfing the predictive power of age (0.819), sex (0.623), histological grade (0.609), pathologic stage (0.545), and nodal or metastatic staging, which fell below 0.5. In both univariate and multivariate Cox regression, the risk score was the only factor significantly associated with overall survival, marking it as an independent prognostic variable rather than a proxy for tumor burden.

Crucially, the model survived contact with external data. In an independent validation cohort of 30 patients from the GEO database (dataset GSE107943), high-risk patients again died at markedly higher rates, and the risk score achieved an area under the curve of 0.789, the best among all tested variables. In this cohort, only vascular invasion and the risk score emerged as significant predictors in multivariate analysis. Subgroup analyses reinforced the biological plausibility of the signature: patients with better-prognosis molecular subclass A tumors showed significantly lower expression of MTHFD1L, SLC16A3, and PYGB, and correspondingly lower risk scores, than those in the poorer-prognosis subclass B.

The team did not stop at computational modeling. Quantitative reverse transcription polymerase chain reaction confirmed that all four genes were expressed at significantly higher levels in two cholangiocarcinoma cell lines, CCLP1 and HuCCT-1, than in immortalized normal biliary epithelial cells. Immunohistochemical data from the Human Protein Atlas showed that the proteins SLC16A3, ACSL4, and PYGB were also elevated in tumor tissue, while MTHFD1L protein was paradoxically lower in tumors despite elevated mRNA, a discrepancy the authors acknowledge and that may reflect post-transcriptional regulation. Each gene carries mechanistic intrigue: SLC16A3, a lactate transporter, is co-activated by mutant KRAS and CK2 to drive tumor progression; ACSL4 participates in ferroptosis, an iron-dependent form of cell death; MTHFD1L is a folate-cycle enzyme implicated in hepatocellular carcinoma; and PYGB, brain-type glycogen phosphorylase, fuels aerobic glycolysis. Notably, PYGB expression showed the strongest and most consistent association with survival across both cohorts, and prior work has shown that inhibiting PYGB slows cholangiocarcinoma progression by reprogramming glycolysis, making it a compelling therapeutic target.

The authors are candid about limitations. The training and validation cohorts were small, retrospective, and drawn from public repositories, and bulk transcriptomic data are vulnerable to technical and biological confounding. Prospective validation in larger, randomized populations or patient-derived xenograft models will be essential before the signature can inform clinical decisions. Even so, the study delivers what the field has lacked: a parsimonious, independently validated metabolic gene model that surpasses traditional staging in predictive accuracy. If larger trials confirm its performance, the four-gene score could help clinicians identify high-risk patients earlier, stratify them for intensified therapy, and, through targets like PYGB and SLC16A3, open new pharmacological avenues in a cancer that urgently needs them.

Subject of Research: A metabolism-related gene signature for predicting prognosis in intrahepatic cholangiocarcinoma

Article Title: A new predictive model for intrahepatic cholangiocarcinoma based on metabolism-related genes

Article References: Li, F., Su, D., Deng, X., Wang, M., Tan, J., Chen, B., He, W., Miao, C., & Zhang, W. (2026). A new predictive model for intrahepatic cholangiocarcinoma based on metabolism-related genes. Heliyon, 12(15), Article e45494. https://doi.org/10.1016/j.heliyon.2026.e45494

Image Credits: AI Generated

DOI: 10.1016/j.heliyon.2026.e45494

Keywords: intrahepatic cholangiocarcinoma, metabolic reprogramming, prognostic model, LASSO Cox regression, PYGB, SLC16A3, ACSL4, MTHFD1L, biomarker, TCGA, gene expression, liver cancer

Depression is among the most burdensome psychiatric conditions worldwide, and a substantial proportion of patients also suffer from gastrointestinal complaints ranging from slowed digestion to impaired barrier function. Current antidepressant therapies, including selective serotonin reuptake inhibitors such as fluoxetine, often deliver suboptimal efficacy and can themselves produce gastrointestinal side effects. That therapeutic gap motivated the research team, led by Li Fan and Qingwei Zhao of the First Affiliated Hospital of Zhejiang University School of Medicine, together with colleagues at Shanghai Jiao Tong University and Central South University, to investigate whether a natural product with a long history of use could act on both the brain and the gut simultaneously.

The team built their study on a chronic restraint stress mouse model, an established paradigm in which animals subjected to prolonged physical restraint develop behavioral and physiological hallmarks that mirror human depression, including gut dysfunction. Mice were divided into five groups: an unstressed control group, a stressed model group, a stressed group treated with the standard antidepressant fluoxetine, and two stressed groups treated with low or high doses of the Cistanche tubulosa total glycosides. All treatments were delivered orally by intragastric gavage over five weeks, a duration chosen to capture both the development of symptoms and the potential for therapeutic reversal.

The behavioral results were striking. Stressed mice that received the glycosides showed a robust restoration of sucrose preference, a standard measure of anhedonia, the loss of pleasure that defines depression. They also displayed increased locomotor activity and greater exploration of the central zones of an open field, both indicators of reduced anxiety-like behavior, and they spent less time immobile in the forced swimming test, another widely used index of behavioral despair. In short, the treated animals looked, by multiple independent behavioral yardsticks, substantially less depressed than their untreated stressed counterparts.

Equally important, the glycosides repaired the gut. Chronically stressed mice typically exhibit multi-segment intestinal dysmotility, and the untreated animals in this study showed prolonged total gut transit time, impaired colonic propulsion, and reduced gastric emptying and intestinal transit rates. Glycoside treatment shortened total transit time, restored colonic propulsion, and enhanced both gastric emptying and intestinal transit. Beyond motility, the treatment preserved the structural integrity of the intestinal barrier: microscopic examination revealed less epithelial damage, and molecular assays showed restored expression of tight junction proteins ZO-1 and occludin as well as the protective mucus component MUC2, all of which are critical to keeping the gut lining sealed against microbial and inflammatory assault.

Inflammation, a well-recognized link between gut dysfunction and mood disorders, also receded under treatment. Levels of the pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 dropped in the intestine, in the serum, and in the hippocampus, the brain region central to emotion and stress regulation. This coordinated reduction across gut, blood, and brain suggests that calming the intestine may send anti-inflammatory signals system-wide, a concept increasingly central to gut-brain axis research. The finding is consistent with the hypothesis that peripheral inflammation contributes to depressive symptomatology and that targeting the gut can modulate neuroinflammation.

To uncover the biochemical pathway underlying these effects, the researchers turned to untargeted metabolomics, an unbiased technique that measures thousands of small molecules simultaneously. The analysis pinpointed arachidonic acid metabolism as the key altered pathway. Treatment with the glycosides decreased cecal levels of arachidonic acid and 20-hydroxy-leukotriene B4 while increasing levels of dinoprost, metabolites with established connections to ferroptosis, an iron-dependent form of regulated cell death driven by the accumulation of lipid peroxides. Ferroptosis has attracted intense scientific interest in recent years because of its roles in neurodegeneration, inflammatory disease, and cancer, but its contribution to gut-brain comorbidity had remained poorly understood.

The mechanistic picture sharpened further with biochemical and molecular assays. The glycosides suppressed intestinal oxidative stress and lipid peroxidation, reduced the accumulation of ferrous iron, and reversed two signature changes in ferroptosis-related proteins: chronic stress had upregulated ACSL4, an enzyme that channels polyunsaturated fatty acids such as arachidonic acid into the lipid pools vulnerable to peroxidation, and had downregulated GPX4, the glutathione-dependent enzyme that normally detoxifies those lipid peroxides. Treatment normalized both. Molecular docking simulations added a final piece: echinacoside, one of the major constituents of the extract, showed strong predicted binding affinity for ACSL4, suggesting a direct molecular interaction that could explain how the glycosides restrain the ferroptotic machinery.

Taken together, the study proposes a coherent and novel pharmacological model. Chronic stress disrupts arachidonic acid metabolism in the gut, fueling ACSL4-mediated ferroptosis that damages the intestinal epithelium, weakens the barrier, and triggers inflammatory cytokine release that reaches the brain. Total glycosides from Cistanche tubulosa intervene at the intestinal source, suppressing ferroptosis, restoring barrier integrity, reducing inflammation, and thereby alleviating depressive-like behaviors. The authors suggest this gut-targeted pathway highlights the potential of these natural compounds as a basis for interventions aimed at comorbid depression and intestinal dysfunction. As with all preclinical work, the findings await validation in human trials, and questions remain about dosing, bioavailability, and long-term safety. Nevertheless, the study adds Cistanche tubulosa glycosides to a growing list of natural products whose effects on ferroptosis and the gut-brain axis are reshaping the search for next-generation antidepressant strategies, and it underscores a message increasingly echoed across neuroscience: to heal the mind, it may sometimes be necessary to begin with the gut.

Subject of Research: Suppression of intestinal ACSL4-mediated ferroptosis by Cistanche tubulosa glycosides to treat comorbid depression and intestinal dysfunction

Article Title: Glycosides from Cistanche tubulosa suppress intestinal ACSL4-mediated ferroptosis to ameliorate depression with intestinal dysfunction symptoms through regulating arachidonic acid metabolism

Article References: Fan, L., Shi, X., Zhao, L., Liu, J., Yang, X., Li, X., & Zhao, Q. (2026). Glycosides from Cistanche tubulosa suppress intestinal ACSL4-mediated ferroptosis to ameliorate depression with intestinal dysfunction symptoms through regulating arachidonic acid metabolism. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05602-0

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05602-0

Keywords: Cistanche tubulosa, glycosides, depression, intestinal dysfunction, ferroptosis, ACSL4, GPX4, arachidonic acid metabolism, gut-brain axis, echinacoside, chronic stress, intestinal barrier

Ferroptosis is an iron-dependent, non-apoptotic form of cell death defined by the catastrophic accumulation of lipid peroxides in cellular membranes. Unlike apoptosis, which cancer cells frequently evade through well-characterized mutations, ferroptosis depends on the lipid composition of the cell, and one enzyme sits at the heart of that dependency: acyl-CoA synthetase long-chain family member 4, commonly abbreviated ACSL4. ACSL4 shapes the membrane pool of oxidizable polyunsaturated fatty acids, and cells with high ACSL4 levels are markedly more vulnerable to ferroptotic death. The new work demonstrates that pancreatic cancer cells actively destroy ACSL4 under hypoxic conditions, and that this destruction is orchestrated by an unexpected player drawn from the machinery of valine, an essential branched-chain amino acid.

The researchers began by comparing tumor samples from patients who responded to gemcitabine-based neoadjuvant chemotherapy with those from non-responders. Metabolomic and transcriptomic profiling revealed that valine, leucine, and isoleucine degradation was significantly enriched in non-responders, and within that pathway the gene encoding MMSDH, ALDH6A1, stood out for its association with poor treatment response and reduced disease-free survival. Transcription factor analysis traced elevated MMSDH expression to SP1, a transcription factor that binds the ALDH6A1 promoter in gemcitabine-resistant tumors, suggesting that the metabolic wiring of these cancers is rewired at the gene expression level before any drug ever enters the cell.

The mechanistic story then deepens in the oxygen-starved interiors of pancreatic tumors. Hypoxia, the researchers found, triggers an enzyme called GCN5 to install a lactyl group, a derivative of lactate, onto MMSDH at the amino acid lysine 113. This modification, known as lactylation, is part of a growing family of metabolite-driven protein modifications that have recently been shown to regulate DNA repair, chromatin biology, and now cancer metabolism. Lactylated MMSDH physically interacts with ACSL4 and, through its catalytic activity, generates propionyl-CoA, a short-chain acyl intermediate of valine catabolism. That propionyl-CoA is then handed to another acetyltransferase, KAT8, which uses it to attach a propionyl group to ACSL4 at lysine 606.

The consequences of this single chemical mark are profound. Propionylation at K606 repositions ACSL4 so that it binds HSC70, the cytosolic chaperone that recognizes the KFERQ-like targeting motifs required for chaperone-mediated autophagy, a selective degradation pathway in which individual proteins are unfolded and threaded into lysosomes. Once flagged in this way, ACSL4 is destroyed, its lipid-remodeling activity collapses, and the tumor cell becomes resistant to the lipid peroxidation that gemcitabine otherwise promotes. Using mass spectrometry, the team confirmed both the K113 lactylation on MMSDH and the K606 propionylation on ACSL4 in hypoxic pancreatic cancer cells, and showed that mutant versions of these proteins that cannot be modified fail to drive ACSL4 degradation or protect cells from ferroptotic death induced by gemcitabine, erastin, or RSL3.

Critically, the findings are not confined to cell culture. In an analysis of patient cohorts, tumors harboring high levels of MMSDH K113 lactylation and ACSL4 K606 propionylation displayed low ACSL4 protein, heightened ferroptosis resistance, and poor clinical response to neoadjuvant chemotherapy. Mouse xenograft experiments extended the picture: tumor cells engineered to express non-modifiable mutants of MMSDH or ACSL4 lost their protective shield and became acutely vulnerable to gemcitabine, while cells bearing the modification-enhancing wild-type enzymes grew aggressively even under low-oxygen conditions and responded poorly to treatment. The team also showed that the same axis operates in lung and ovarian cancer cell lines, hinting that MMSDH-mediated ACSL4 propionylation may be a broader mechanism of ferroptosis evasion across solid tumors.

Perhaps the most translational aspect of the study lies in two therapeutic strategies the authors developed to disrupt this axis. The first is dietary: because MMSDH is a valine catabolism enzyme that depends on valine-derived substrate to generate propionyl-CoA, restricting dietary valine in mice starved the pathway of its fuel. Combining valine-restricted diets with gemcitabine synergistically restored lipid peroxidation and suppressed tumor growth, notably without causing significant toxicity, weight loss, or metabolic distress in the animals. The second approach is pharmacological: the team designed cell-penetrating blocking peptides centered on the lactylated K113 sequence of MMSDH. A lead peptide disrupted the interaction between lactylated MMSDH and ACSL4, prevented ACSL4 propionylation and degradation, restored ferroptotic sensitivity, and markedly potentiated gemcitabine in both subcutaneous and orthotopic pancreatic tumor models while improving animal survival.

Beyond the immediate therapeutic implications, the study expands the conceptual map of how post-translational modifications couple cellular metabolism to cell fate. Amino acid catabolic enzymes are increasingly appreciated as moonlighting regulators of signaling and protein stability, and this work adds a new chapter by showing that a valine-processing enzyme can be co-opted by hypoxia-driven lactylation to flag a ferroptosis gatekeeper for lysosomal destruction. It also illustrates a chemical relay of remarkable economy: hypoxia produces lactate, lactate lactylates MMSDH, lactylated MMSDH produces propionyl-CoA from valine, and propionyl-CoA propionylates ACSL4, linking three metabolic programs, glycolysis, branched-chain amino acid catabolism, and lipid metabolism, into a single survival circuit. The authors’ clinical data suggest that MMSDH K113 lactylation and ACSL4 K606 propionylation may serve as biomarkers for predicting which pancreatic cancer patients will benefit from gemcitabine-based neoadjuvant regimens, potentially guiding treatment selection in a disease where therapeutic options remain painfully limited.

Challenges remain before this biology reaches the clinic. Blocking peptides must be optimized for delivery, stability, and specificity in humans, and dietary valine restriction will need careful evaluation in clinical trials, particularly given the catabolic state of many pancreatic cancer patients. Yet the study provides something pancreatic oncology has long needed: a mechanistically resolved, chemically validated, and clinically correlated explanation for why so many tumors shrug off chemotherapy, together with concrete tools to break that resistance. By exposing the GCN5-MMSDH-ACSL4 axis, the Zhejiang University team has turned a metabolic quirk of hypoxic tumor cells into a target, and in doing so opened a plausible path toward making ferroptosis-inducing chemotherapy a reality for one of medicine’s most intractable cancers.

Subject of Research: Hypoxia-driven MMSDH lactylation and ACSL4 propionylation as a mechanism of ferroptosis evasion and chemotherapy resistance in pancreatic ductal adenocarcinoma

Article Title: MMSDH facilitates ACSL4 propionylation to counteract ferroptosis upon hypoxia and impairs PDAC chemotherapy efficacy

Article References: Zheng, P., Lin, Y., Zhang, M., Tang, Z., Qin, W., Xiao, M., Sun, X., Shen, Y., Hu, Z., Ru, S., Duan, Y., Dong, B., Wen, T., Li, M., Wu, H., Hou, Y., Ji, G., Wang, Z., Wu, X., … Xu, D. (2026). MMSDH facilitates ACSL4 propionylation to counteract ferroptosis upon hypoxia and impairs PDAC chemotherapy efficacy. Nature Cancer. https://doi.org/10.1038/s43018-026-01236-w

Image Credits: AI Generated

DOI: 10.1038/s43018-026-01236-w

Keywords: pancreatic ductal adenocarcinoma, ferroptosis, MMSDH, ACSL4, lactylation, propionylation, hypoxia, gemcitabine resistance, chaperone-mediated autophagy, valine metabolism, GCN5, KAT8